ProQR Therapeutics today announced positive results from a planned analysis of its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations.
… Phase 2/3 Illuminate trial results of sepofarsen in CEP290-mediated LCA10 In … French and German . Illuminate Illuminate is the name of a clinical study which aimed to explore whether the … an injection with no medicine or injection given. Clinicaltrials are used by researchers to find out whether new …
… Conference call top-line results Phase 2/3 Illuminate trial Webcast information Company management will host a call … discuss the top-line results of the Phase 2/3 Illuminate clinicaltrial of investigational RNA therapy sepofarsen in …
… ProQR Announces Clearance of IND to Start ClinicalTrial of QR-421a in Usher Syndrome Type 2 Patients LEIDEN, … To date, there are no approved treatments or products in clinical development that treat the vision loss associated …
